Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Pharmacoepidemiology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1463560
This article is part of the Research Topic Advances in Drug-induced Diseases Volume II View all 26 articles

A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA Adverse Events Reporting System (FAERS) database from 2013(Q4) to 2024 (Q1)

Provisionally accepted
Tang Huafei Tang Huafei 1Xu Jing Xu Jing 2*Zhang Xian Zhang Xian 1*Chen Chunliang Chen Chunliang 1*Ge Song Ge Song 3Ma Rui Ma Rui 1*ZHAO Jinjing ZHAO Jinjing 3*Zhao Qiang Zhao Qiang 1*
  • 1 Department of Pharmacy, The 305 Hospital of PLA, Beijing, China
  • 2 Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, China
  • 3 Department of Neurology, The 305 Hospital of PLA, Beijing, China

The final, formatted version of the article will be published soon.

    The principal aim of the present study was to scrutinize eslicarbazepine acetate related AEs by leveraging data from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. Methods: By extracting all available data since the FDA approval of ESL (2013Q4-2024Q1), disproportionality analysis was performed using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN) and multi-item gamma Poisson shrinker (MGPS) algorithms. Demographic information, time of onset and gender-specific signal detection were also examined. In addition, a special screening process for designated medical events (DME) was implemented to focus on the evaluation and comparison of safety signals within DME and System Organ Classification (SOC) level, as well as SMQ (Standardised MedDRA Queries) level. Stratified analysis by logistic regression is employed to examine the variations across different gender and age groups. Results: A total of 5,719 AE reports and 1,907 reported cases were obtained. ESL related AEs were identified in relation to 27 SOCs, among which the significant positive SOCs were nervous system disorders , injury poisoning and procedural complications, etel. There were 86 severely disproportional preferred terms that complied with the four algorithms. Most AEs occurred within the first month after treatment. According to the 86 valuable positive signals with DME screening results, 3 signals of dermatitis exfoliative, stevens-johnson syndrome, drug reaction with eosinophilia and systemic symptoms were consistent with PT signals on the DME-list, with the 3 PTs focusing on skin and subcutaneous tissue disorders and hypersensitivity. Males are more commonly affected by seizures than females. Seizures, hyponatremia, and confusional states were more frequently observed in the elderly population, while aggression, irritability, DRESS, and abnormal behavior were found to be more common in the pediatric population. Both the children and elderly groups exhibited a higher proportion of agitation than the adult group. Conclusion: Our research enhances the safety and tolerability profile of ESL, but the clinical use of ESL should be noticed and avoided in relation to AEs since it raises the risk of dermatitis exfoliative, stevens-johnson syndrome. Particular attention should be paid to DRESS in children and hyponatremia in the elderly.

    Keywords: eslicarbazepine acetate, ESL, fda, pharmacovigilance analysis, AES

    Received: 12 Jul 2024; Accepted: 11 Sep 2024.

    Copyright: © 2024 Huafei, Jing, Xian, Chunliang, Song, Rui, Jinjing and Qiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xu Jing, Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, China
    Zhang Xian, Department of Pharmacy, The 305 Hospital of PLA, Beijing, China
    Chen Chunliang, Department of Pharmacy, The 305 Hospital of PLA, Beijing, China
    Ma Rui, Department of Pharmacy, The 305 Hospital of PLA, Beijing, China
    ZHAO Jinjing, Department of Neurology, The 305 Hospital of PLA, Beijing, China
    Zhao Qiang, Department of Pharmacy, The 305 Hospital of PLA, Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.